Engineered from the NK-92 immortalized lymphoma cell line to have the capacity to mediate ADCC through expression of a CD16 high affinity FcγRIIIa receptor and produce endogenous IL-2 [9, 10], haNKs expand readily in culture and represent an “off the shelf” NK cellular therapeutic that is currently in clinical trials to treat advanced solid malignancies (NCT03027128). The gene discussed is IL2; the disease is lymphoma.